Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study

Incorporating genomic sequencing into newborn screening will dramatically increase the number of detectable conditions but evidence is needed to guide policy. The prospective BabyScreen+ cohort study screened 1,000 newborns from the state of Victoria, Australia for variants in 605 genes associated with early-onset, severe, treatable conditions using whole-genome sequencing performed on dried blood spot cards. Sixteen infants (1.6%) were identified as having high-chance results. Of these, only one was detected by standard newborn screening. Average time to genomic newborn result was 13 days. Clinical impact ranged from instituting preventative measures or surveillance to active management, including transplantation. Twenty relatives received a diagnosis following cascade testing. Median parental decisional regret was low (median 0, interquartile range 0-10); >99% of participants thought genomic newborn screening should be available to all parents. Our study demonstrates the feasibility of clinically accredited genomic newborn screening, using a scalable model that is highly acceptable to parents. Future research is needed to address issues of scalability and equity.

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2025-10-09
DOI
https://doi.org/10.1038/s41591-025-03986-z
Citations
8
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
14.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study

Crystle Lee, Sebastian Hollizeck, Ronda F. Greaves, Jessica R. Riseley et al.
8 citations
Nature Medicine
Genomics and Rare Diseases
14.54
article

Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study

Crystle Lee, Sebastian Hollizeck, Ronda F. Greaves, Jessica R. Riseley, Paul De Fazio, Marc Clausen, Christopher Gyngell, Sebastian Lunke, Anthony Marty, Anaita Kanga‐Parabia, Ee Ming Wong, Fiona Lynch, Ilias Goranitis, Jade Caruana, Yvonne Bombard, Lilian Downie, Simon Sadedin, Clara Gaff, John Christodoulou, Melanie A. Marty, Erin Tutty, Sophie E. Bouffler, Meaghan Wall, Zornitza Stark, Alison D. Archibald, David J. Amor, Alison Yeung, Stephanie Best, Danya F. Vears, Katrina L. Scarff, Candice McGregor, Monica Torres, Nitzan Lang, Nathasha Kugenthiran, Wendy Fagan, Ching Vang
article en
8 citations

Abstract

Incorporating genomic sequencing into newborn screening will dramatically increase the number of detectable conditions but evidence is needed to guide policy. The prospective BabyScreen+ cohort study screened 1,000 newborns from the state of Victoria, Australia for variants in 605 genes associated with early-onset, severe, treatable conditions using whole-genome sequencing performed on dried blood spot cards. Sixteen infants (1.6%) were identified as having high-chance results. Of these, only one was detected by standard newborn screening. Average time to genomic newborn result was 13 days. Clinical impact ranged from instituting preventative measures or surveillance to active management, including transplantation. Twenty relatives received a diagnosis following cascade testing. Median parental decisional regret was low (median 0, interquartile range 0-10); >99% of participants thought genomic newborn screening should be available to all parents. Our study demonstrates the feasibility of clinically accredited genomic newborn screening, using a scalable model that is highly acceptable to parents. Future research is needed to address issues of scalability and equity.

Nature MedicineVol. 31(12)
Deakin University (AU), The University of Melbourne (AU), University of Toronto (CA), Walter and Eliza Hall Institute of Medical Research (AU), Ontario Genomics (CA), Victorian Clinical Genetics Services (AU), Zoos Victoria (AU), Murdoch Children's Research Institute (AU), Melbourne Genomics Health Alliance (AU)
Children's Hospital Foundation, Australian Government, State Government of Victoria, Medical Research Council, National Health and Medical Research Council
Openalex Percentile: Top 1%
Genomics and Rare Diseases
14.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.